Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine
China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...
MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...
Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment
Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...
QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...
Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China
Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...
Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution
Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...
CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...
Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform
Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...
AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech
Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...
Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...
Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...
Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...